ML385|cas:846557-71-9|西域试剂

ML385,99.72%

产品编号：Bellancom-100523| CAS NO：846557-71-9| 分子式：C₂₉H₂₅N₃O₄S| 分子量：511.59

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100523	￥750.00	杭州北京（现货）
Bellancom-100523	￥1300.00	杭州北京（现货）
Bellancom-100523	￥2850.00	杭州北京（现货）
Bellancom-100523	￥4950.00	杭州北京（现货）
Bellancom-100523	￥8900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ML385

产品介绍

ML385是特异的 NRF2 抑制剂，IC₅₀ 为1.9 μM。

生物活性

ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor with an IC₅₀ of 1.9 μM.

体外研究

ML385 interacts with NRF2 and affects the DNA binding activity of the NRF2-MAFG protein complex. The addition of ML385 decreases anisotropy in a dose-dependent manner, with an IC₅₀ of 1.9 μM. A dose-dependent reduction in the NRF2 transcriptional activity is observed and the maximum inhibitory concentration is 5 μM by ML385. Treatment with ML385 leads to a significant reduction in NRF2 and downstream target gene expression selectively in KEAP1 mutant H460 cells. ML385 selectively affects the colony forming ability or growth of lung cancer cells with gain of NRF2 function.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ML385 in combination with carboplatin leads to a significant reduction in tumor cell proliferation, demonstrated by fewer Ki-67 positive cells. Tumor samples treated with ML385 show a significant reduction in NRF2 protein level and its downstream target genes.
ML385 (intraperitoneal injection; 30 mg/kg; 7 days) weakens the therapeutic effects of MSC-Exo on inflammation-induced astrocytic activation in mice, and reduces reactive astrogliosis, NF-κB deactivation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-week-old C57B/6 male mice
Dosage:	30 mg/kg; 7 days
Administration:	Intraperitoneal injection
Result:	Reversed inhibition of MSC-Exo on hippocampal astrocytic activation in vivo.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-week-old C57B/6 male mice
Dosage:	30 mg/kg; 7 days
Administration:	Intraperitoneal injection
Result:	Reversed inhibition of MSC-Exo on hippocampal astrocytic activation in vivo.

性状

Solid

溶解性数据

In Vitro:

DMSO : 33.33 mg/mL (65.15 mM; ultrasonic and warming and heat to 60°C)

H₂O : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9547 mL	9.7735 mL	19.5469 mL
5 mM	0.3909 mL	1.9547 mL	3.9094 mL
10 mM	0.1955 mL	0.9773 mL	1.9547 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 50% PEG300 50% saline
Solubility: 10 mg/mL (19.55 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 9.01 mg/mL (17.61 mM); Clear solution; Need ultrasonic
3.

请依序添加每种溶剂： 15% Solutol HS 15 10% Cremophor EL 35% PEG 400 40% water
Solubility: 5 mg/mL (9.77 mM); Suspended solution; Need ultrasonic
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.89 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.89 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
5.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.07 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.07 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液